NR1H4 and metabolic dysfunction-associated steatohepatitis: Obeticholic acid (OCA, INT-747) is a derivative of CDCA and a selective FXR agonist as a leading candidate in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) [128].